Current immunotherapy utilises monoclonal antibodies targeting programmed cell death 1 (PD1) such as pembrolizumab and nivolumab, which have demonstrated improved survival only in metastatic dmmR-mSI-H CRC [10]. Here, PDCD1 is linked to colorectal carcinoma.